Gedatolisib (PF-05212384, PKI-587)


Gedatolisib (PF-05212384, PKI-587)化学構造


Gedatolisib (PF-05212384, PKI-587)は一種の有効な二重PI3Kα、PI3KγとmTOR阻害剤で、無細胞試験でIC50値が0.4 nM、5.4 nMと1.6 nMそれぞれに分かれます。臨床2期。

サイズ 価格 在庫  
USD 214 あり
USD 340 あり
USD 844 あり


  • PI3K inhibitors promote apoptosis in checkpoint-defective cell lines. Two checkpoint-functional (A2058, D28) and three defective (HT144, D20, SKMel13) melanoma cell lines growth as tumour spheres as in Figure 4B were either untreated or treated with 5 uM PF-05212384 for 72 h, harvested and immunoblotted for pAkt Ser473.

    Pigment Cell Melanoma Res 2014 27(5), 813-21. Gedatolisib (PF-05212384, PKI-587) purchased from Selleck.

    After starved in serum-free medium for 24h,A549 cells incubated with the indicated concentrations of PKI-587 for 3h,followed by 20-minute stimolation of 100ng/ml EGF.

    Dr. Zhang of Tianjin Medical University. Gedatolisib (PF-05212384, PKI-587) purchased from Selleck.




製品説明 Gedatolisib (PF-05212384, PKI-587)は一種の有効な二重PI3Kα、PI3KγとmTOR阻害剤で、無細胞試験でIC50値が0.4 nM、5.4 nMと1.6 nMそれぞれに分かれます。臨床2期。
PI3Kα [1]
(Cell-free assay)
mTOR [1]
(Cell-free assay)
PI3Kγ [1]
(Cell-free assay)
0.4 nM 1.6 nM 5.4 nM

PKI-587 shows potent inhibitory activity against PI3K-α, PI3K-γ and mTOR with IC50 of 0.4 nM, 5.4 nM and 1.6 nM, respectively. Furthermore, PKI-587 also exhibits its potency against the most frequently occurring mutant forms of PI3Kα, notably the H1047R and E545K with IC50 of 0.6 nM and 0.6 nM, respectively. [1] Correlated with suppression of phosphorylation of PI3K/mTOR signaling pathway proteins, PKI-587 causes tumor cell growth inhibition in MDA-361 and PC3-MM2 cell lines with IC50 of 4 nM and 13.1 nM, respectively. [1]

体内試験 In nude mice, PKI-587 treatment at 25 mg/kg iv leads to low plasma clearance (7 (mL/min)/kg), high volume of distribution (7.2 L/kg), and long half-life, (14.4 hours). In the MDA-361 xenograft model, PKI-587 produces potent antitumor efficacy with the minimum efficacious dose (MED) of 3 mg/kg against MDA-361 tumors and maximum tolerated single dose (MTD) of 30 mg/kg. While in the H1975 (non-small-cell lung carcinoma, mutant EGFR [L858R, T790M]) xenograft model, PKI-587 at 25 mg/kg for 7 weeks results in 90% survival of the group treated. [1]


+ 展開

PI3K and mTOR kinase assay :

Enzyme assays are done in fluorescent polarization (FP) format, adapted from the Echelon K-1100 PI3K FP assay kit protocol. Human class I PI3Ks and PI3K-α mutants (E545K and H1047R) are produced in Sf9 or purchased from Upstate Biotech. GST-GRP1 (murine) is produced in Escherichia coli and isolated by GST-Sepharose. Assay buffers are reaction buffer [20 mM HEPES (pH 7.1), 2 mM MgCl2, 0.05% CHAPS, and 0.01% β-mercaptoethanol] and stop/detection buffer [100 mM HEPES (pH 7.5), 4 mM EDTA, 0.05% CHAPS]. FP reaction is run for 30 minutes at room temperature in 20 μL of reaction buffer containing 20 μM phosphatidylinositol 4,5-bisphosphate (PIP2), 25 μM ATP, and <4% DMSO. FP reaction is stopped with 20 μL of stop/detection buffer (10 nM probe and 40 nM GST-GRP), and after 2 hours, data are collected using an Envision plate reader. The routine assays with purified FLAG-TOR (FL and 3.5) are performed in 96-well plates as follows. Enzymes are first diluted in kinase assay buffer (10 mM Hepes (pH 7.4), 50 mM NaCl, 50 mM β-glycerophosphate, 10 mM MnCl2, 0.5 mM DTT, 0.25 μM microcystin LR, and 100 μg/mL BSA). To each well, 12 μL of the diluted enzyme is mixed briefly with 0.5 μL test inhibitor or control vehicle dimethyl sulfoxide (DMSO). The kinase reaction is initiated by adding 12.5 μL kinase assay buffer containing ATP and His6-S6K to give a final reaction volume of 25 μL containing 800 ng/mL FLAG-TOR, 100 μM ATP, and 1.25 μM His6-S6K. The reaction plate is incubated for 2 hours (linear at 1–6 hours) at room temperature with gentle shaking and then terminated by adding 25 μL Stop buffer (20 mM Hepes (pH 7.4), 20 mM EDTA, and 20 mM EGTA).
細胞試験: [1]
+ 展開
  • 細胞株: MDA-361 and PC3-MM2
  • 濃度: 0-10 μM
  • 反応時間: 72 hours
  • 実験の流れ: Cells are plated in 96-well culture plates at about 3000 cells per well. One day following plating, PKI-587 is added to cells. Three days after PKI-587 treatment, viable cell densities are determined by measuring metabolic conversion (by viable cells) of the dye MTS, a previously established cell proliferation assay. For each assay, MTS and PMS stocks are freshly thawed and mixed (MTS/PMS, 20:1). The MTS/PMS mixture is then added to 96-well cell plates at 20 μL/well, and plates are incubated for 1 hour–2 hours in cell culture incubator. MTS assay results are read in a 96-well format plate reader by measuring absorbance at 490 nm. The effect of each PKI-587 treatment is calculated as a percentage of control cell growth obtained from vehicle-treated cells grown in the same culture plate.
+ 展開
  • 動物モデル: MDA-361 and H1975 cells are injected subcutaneously into the nude mice.
  • 製剤: Dissolved in 5% dextrose [D5/W], 0.3% lactic acid.
  • 投薬量: ≤30 mg/kg
  • 投与方法: Administered via i.v.

溶解度 (25°C)

体外 DMSO 2 mg/mL (3.24 mM)
Water slightly soluble or insoluble
Ethanol slightly soluble or insoluble

* 溶解度検測はSelleck技術部門によって行いますので、文献より提供された溶解度と差異がある可能性がありますが、生産工芸と不同ロット(lot)で起きる正常な現象ですから、ご安心ください。


分子量 615.73


CAS No. 1197160-78-3
in solvent
別名 N/A





マス (g) = 濃度 (mol/L) x ボリューム (L) x 分子量 (g/mol)


  • マス




貯蔵液を準備することを要求される希釈剤を計算してください. セレック希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積


この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 輸入 輸出 )

  • C1



  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):




チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2


マス 濃度 ボリューム 分子量


NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02438761 Active, not recruiting Therapy-related Acute Myeloid Leukemia and Myelodysplastic Syndrome|Acute Myeloid Leukemia, in Relapse|de Novo Acute Myeloid Leukemia at Diagnostic Institut Curie|Fondation ARC|National Cancer Institute, France August 31, 2015 Phase 2
NCT02142920 Completed Healthy Pfizer July 2014 Phase 1
NCT02069158 Recruiting Breast Cancer|NSCLC|Ovary Cancer|Endometrial Cancer|Small Cell Lung Cancer (SCLC)|Head and Neck (HNSCC) Cristiana Sessa|Oncology Institute of Southern Switzerland April 2014 Phase 1
NCT01937715 Terminated Metastatic Colorectal Carcinoma Pfizer February 2014 Phase 1|Phase 2
NCT01925274 Terminated Metastatic Colorectal Cancer Pfizer November 2013 Phase 2
NCT01920061 Recruiting Neoplasm Pfizer September 2013 Phase 1



Handling Instructions


  • * 必須


PI3K Inhibitors with Unique Features


Tags: Gedatolisib (PF-05212384, PKI-587)を買う | Gedatolisib (PF-05212384, PKI-587) ic50 | Gedatolisib (PF-05212384, PKI-587)供給者 | Gedatolisib (PF-05212384, PKI-587)を購入する | Gedatolisib (PF-05212384, PKI-587)費用 | Gedatolisib (PF-05212384, PKI-587)生産者 | オーダーGedatolisib (PF-05212384, PKI-587) | Gedatolisib (PF-05212384, PKI-587)化学構造 | Gedatolisib (PF-05212384, PKI-587)分子量 | Gedatolisib (PF-05212384, PKI-587)代理店
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID